EQL Pharma - Public Comps and Valuation Multiples

EQL Pharma Overview

About EQL Pharma

EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.

Founded

2006

HQ

Employees

Website

eqlpharma.com

Sectors

Drug Development & Therapeutics
Biopharmaceuticals
BioTech

Financials

LTM Revenue $45.6M

LTM EBITDA $10.7M

EV

$230M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

EQL Pharma Financials

As of September 2025, EQL Pharma reported last 12-month revenue of $45.6M and EBITDA of $10.7M.

In the same period, EQL Pharma generated $19.7M in LTM gross profit and $5.2M in net income.

See EQL Pharma valuation multiples based on analyst estimates

EQL Pharma P&L

In the most recent fiscal year, EQL Pharma reported revenue of $39.3M and EBITDA of $8.3M.

EQL Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See EQL Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$45.6M	XXX	$39.3M	XXX	XXX	XXX
Gross Profit	$19.7M	XXX	$16.4M	XXX	XXX	XXX
Gross Margin	43%	XXX	42%	XXX	XXX	XXX
EBITDA	$10.7M	XXX	$8.3M	XXX	XXX	XXX
EBITDA Margin	24%	XXX	21%	XXX	XXX	XXX
EBIT	$8.6M	XXX	$7.0M	XXX	XXX	XXX
EBIT Margin	19%	XXX	18%	XXX	XXX	XXX
Net Profit	$5.2M	XXX	$4.5M	XXX	XXX	XXX
Net Margin	11%	XXX	12%	XXX	XXX	XXX
Net Debt	XXX	XXX	$38.7M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for EQL Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $45.6M. EBITDA for the last twelve months was $10.7M. In the most recent fiscal year, EQL Pharma achieved $39.3M in revenue and $8.3M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$45.6M	Analyst estimates available to subscribers	$39.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$19.7M	Analyst estimates available to subscribers	$16.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	43.3% gross margin	Analyst estimates available to subscribers	41.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$10.7M	Analyst estimates available to subscribers	$8.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	23.6% EBITDA margin	Analyst estimates available to subscribers	21.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$8.6M	Analyst estimates available to subscribers	$7.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	18.9% EBIT margin	Analyst estimates available to subscribers	17.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$5.2M	Analyst estimates available to subscribers	$4.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	11.3% net profit margin	Analyst estimates available to subscribers	11.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$38.7M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for EQL Pharma

This financial data table provides comprehensive performance metrics for EQL Pharma, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

EQL Pharma generated $45.6M in revenue over the last twelve months.
The company achieved $10.7M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $19.7M.
Net income over the last twelve months reached $5.2M.

Fiscal Year Performance

In the most recent fiscal year, EQL Pharma reported $39.3M in total revenue.
Fiscal year EBITDA was $8.3M.
The company maintained a gross profit margin of 41.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 21.2%.
Net profit margin reached 11.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for EQL Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

EQL Pharma Stock Performance

EQL Pharma has current market cap of SEK 1.8B (or $186M), and EV of SEK 2.2B (or $230M).

Market Cap Evolution

EQL Pharma Stock Data

As of October 17, 2025, EQL Pharma's stock price is SEK 60 (or $6).

See EQL Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$230M	$186M	XXX	XXX	XXX	XXX	$0.18

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

EQL Pharma Valuation Multiples

EQL Pharma's trades at 6.3x EV/Revenue multiple, and 31.2x EV/EBITDA.

See valuation multiples for EQL Pharma and 15K+ public comps

EQL Pharma Financial Valuation Multiples

As of October 17, 2025, EQL Pharma has market cap of $186M and EV of $230M.

Equity research analysts estimate EQL Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

EQL Pharma has a P/E ratio of 36.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$186M	XXX	$186M	XXX	XXX	XXX
EV (current)	$230M	XXX	$230M	XXX	XXX	XXX
EV/Revenue	5.0x	XXX	6.3x	XXX	XXX	XXX
EV/EBITDA	21.4x	XXX	31.2x	XXX	XXX	XXX
EV/EBIT	26.7x	XXX	37.9x	XXX	XXX	XXX
EV/Gross Profit	11.7x	XXX	n/a	XXX	XXX	XXX
P/E	36.2x	XXX	46.6x	XXX	XXX	XXX
EV/FCF	-19.2x	XXX	-9.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get EQL Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

EQL Pharma Margins & Growth Rates

EQL Pharma's last 12 month revenue growth is 30%

EQL Pharma's revenue per employee in the last FY averaged $1.9M, while opex per employee averaged $0.4M for the same period.

EQL Pharma's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

EQL Pharma's rule of X is 98% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for EQL Pharma and other 15K+ public comps

EQL Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	30%	XXX	31%	XXX	XXX	XXX
EBITDA Margin	24%	XXX	20%	XXX	XXX	XXX
EBITDA Growth	36%	XXX	44%	XXX	XXX	XXX
Rule of 40	50%	XXX	50%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	98%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.9M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	16%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	24%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial